NOVARTIS AG N (NOT) Stock Analysis
Verdict: BUY
Post-Sandoz margin expansion and robust 9% Revenue CAGR justify a valuation rerating, despite rising debt levels to fund R&D.
Investment score: 72/100
Analysis as of
Is NOVARTIS AG N stock worth reviewing? The TradeMates thesis
Novartis is successfully executing its transition to a high-margin innovative medicines company. With revenue growing at a 9% clip and EPS nearly doubling over a three-year window, the current valuation fails to fully capture the structural improvement in profitability.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 88/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 78/100 (weight 15%)
NOVARTIS AG N opportunities and risks
What speaks for NOT
- Structural Margin Expansion
What speaks against NOT
- Rising Debt Load
Frequently asked questions about NOVARTIS AG N (NOT)
Is NOT stock a good investment?
The TradeMates model rates NOVARTIS AG N as BUY with an investment score of 72/100. Novartis is successfully executing its transition to a high-margin innovative medicines company. With revenue growing at a 9% clip and EPS nearly doubling over a three-year window, the current valuation fails to fully capture the structural improvement in profitability. This is algorithmic model output, not personal investment advice.
Is NOT stock a buy?
The TradeMates model verdict for NOT is BUY with an investment score of 72/100. Treat this as a model signal to review, not a personal buy recommendation.